Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

PREGNANT Short Cervix Trial

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00615550
Recruitment Status : Completed
First Posted : February 14, 2008
Results First Posted : March 13, 2012
Last Update Posted : March 13, 2012
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Information provided by (Responsible Party):
Juniper Pharmaceuticals, Inc.

Brief Summary:
The purpose of this research study is to evaluate the usefulness of progesterone vaginal gel in decreasing the preterm birth rate in a population of pregnant women with short cervical length and at high risk for preterm birth.

Condition or disease Intervention/treatment Phase
Preterm Delivery Short Cervix Short Uterine Cervical Length Drug: progesterone Drug: placebo Phase 3

Detailed Description:
A Short uterine cervical length in the mid-trimester is the most powerful predictor of preterm birth.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 465 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: The Effect of Vaginal Progesterone Administration in the Prevention of Preterm Birth in Women With a Short Cervix [Vaginal Progesterone Bioadhesive Gel (Prochieve)® Extending Gestation A New Therapy for Short Cervix - Trial (PREGNANT Short Cervix - Trial)]
Study Start Date : March 2008
Actual Primary Completion Date : November 2010
Actual Study Completion Date : November 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Pregnancy

Arm Intervention/treatment
Placebo Comparator: Placebo
placebo vaginal gel
Drug: placebo
vaginal gel, 1.125 Grams once daily, beginning at 19 0/7 to 23 6/7 weeks gestation through 36 6/7 weeks gestation

Active Comparator: Prochieve
Progesterone 8% Vaginal Gel
Drug: progesterone
8% vaginal gel, 1.125 Grams once daily, beginning at 19 0/7 to 23 6/7 weeks gestation through 36 6/7 weeks gestation
Other Name: Prochieve 8%

Primary Outcome Measures :
  1. Number of Participants With Birth <=32 6/7 Weeks Gestation. [ Time Frame: 9 to 13 weeks ]

Secondary Outcome Measures :
  1. Number of Infants With Neonatal Morbidities Such as Respiratory Distress Syndrome (RDS), Bronchopulmonary Dysplasia (BPD), Intraventricular Hemorrhage (IVH), Proven Sepsis, and Necrotizing Enterocolitis (NEC) [ Time Frame: Delivery Hospitalization (1-212 days) ]

    Each infant is scored based on the 7 morbidity and mortality events above:

    0= no morbidity event

    1. 1 morbidity event
    2. 2 morbidity events
    3. 3 or more morbidity events
    4. mortality

  2. Number of Subjects With Preterm Birth at ≤27 6/7, ≤34 6/7, and <36 6/7 Weeks Gestation. [ Time Frame: Gestational Age at Delivery ]
    Number of participants at <=27 6/7 , <=34 6/7, and <36 6/7.

  3. Number of Neonates Who Died. [ Time Frame: Delivery to 28 days ]
  4. Number of Infants With a Birth Weight < 1500 Grams or < 2500 Grams [ Time Frame: date of delivery ]
    Assessment of birth weight < 1500 grams or < 2500 grams

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   15 Years to 45 Years   (Child, Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. The subject has a short cervical length by transvaginal ultrasound (TVU) defined as 10-20mm. In cases of "dynamic cervix", the shortest observed/documented cervical length by TVU is to be used as the cervical length for inclusion purposes.
  2. Singleton gestation.
  3. The pregnancy has an estimated gestational age between 19 0/7 weeks and 23 6/7 weeks.
  4. Maternal age between 15 (or local age of majority/emancipation) and 45 years of age at the time of screening. An alternative age range can be accepted according to the standards and applicable regulations of the study centers.
  5. The subject speaks either English or a common local language.
  6. The subject has voluntarily signed the Informed Consent Form and associated forms after having the contents explained, and all her questions are answered to her satisfaction and understanding.
  7. In the opinion of the investigator, the subject is able to understand the study and is able to give informed consent, as well as participate in it and adhere to study procedures.

Exclusion Criteria:

  1. The subject has a cervical length <10 or >20mm.
  2. The subject has a multifetal gestation.
  3. The subject has or is scheduled to have a cervical cerclage prior to randomization. According to ACOG Practice Bulletin Number 48 (November 2003), cerclage can be considered in a subject with a history of 3 or more unexplained midtrimester pregnancy losses or preterm deliveries.228,229
  4. Subjects diagnosed to have acute cervical insufficiency with bulging membranes passing the external os.
  5. The subject has a previous history of an adverse reaction to progesterone or any component present in Prochieve® 8% vaginal gel.
  6. The subject has been treated with a progestogen within the previous 4 weeks.
  7. The subject is currently being treated for a seizure disorder, has an unstable psychiatric disorder, is taking antihypertensive therapy for chronic hypertension at the time of enrollment, has a history of congestive heart failure or chronic renal failure, or has uncontrolled diabetes mellitus (known end-organ dysfunction secondary to vascular disease).
  8. The subject has active thrombophlebitis or a thromboembolic disorder, or a history of hormone-associated thrombophlebitis or thromboembolic disorders.
  9. The subject has active liver dysfunction or disease.
  10. The subject has known or suspected malignancy of the breast or genital organs.
  11. The subject is currently participating in another interventional study or has participated in an interventional drug study within one month prior to screening for this study.
  12. The subject's current pregnancy is complicated by a major fetal anomaly or known chromosomal abnormality.
  13. The subject has a uterine anatomic malformation (bicornuate uterus, septate uterus)
  14. The subject, in the judgment of the investigator, will be unable or unwilling to comply with study-related assessments and procedures.
  15. The subject currently has preterm rupture of membranes, vaginal bleeding, known or suspected amnionitis, or signs or symptoms of preterm labor at the time of enrollment.
  16. The subject is HIV positive with a CD4 count of <350 cells/mm3 and is receiving more than one (1) medication to prevent the transfer of AIDS to the fetus.
  17. Complete placenta previa.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00615550

Show Show 49 study locations
Sponsors and Collaborators
Juniper Pharmaceuticals, Inc.
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Layout table for investigator information
Study Director: George W. Creasy, MD, FACOG Columbia Laboratories, Inc.
Study Director: Roberto Romero, MD Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Study Director: Sonia Hassan, MD Wayne State University
Additional Information:
Publications of Results:
Other Publications:
Layout table for additonal information
Responsible Party: Juniper Pharmaceuticals, Inc. Identifier: NCT00615550    
Other Study ID Numbers: COL-1620-302
First Posted: February 14, 2008    Key Record Dates
Results First Posted: March 13, 2012
Last Update Posted: March 13, 2012
Last Verified: February 2012
Keywords provided by Juniper Pharmaceuticals, Inc.:
Additional relevant MeSH terms:
Layout table for MeSH terms
Premature Birth
Obstetric Labor, Premature
Obstetric Labor Complications
Pregnancy Complications
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs